prospective comparison of safety , efficacy and cost effectiveness of various treatment regimen in type 2 diabetes mellitus

A PROSPECTIVE STUDY FOR THE COMPARATIVE EVALUATION OF SAFETY, EFFICACY AND COST EFFECTIVENESS OF VARIOUS ADD ON TREATMENT REGIMEN IN TYPE 2 DIABETES PATIENTS, NOT CONTROLLED BY METFORMIN ALONE

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2014/02/004435

Enrollment

150

Registered

2014-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 diabetes mellitus

Interventions

Control Intervention1: sulfonylurea + metformin combination, Thiazolidinediones+metformin combination and DPP4 inhibitor+metformin combination: The doses of all the drugs were as per the requirement o

Eligibility

Inclusion criteria

Inclusion criteria: - type 2 diabetes mellitus either newly diagnosed or previously established with baseline HbA1c >=7% - not controlled by metformin alone needing additional antihyperglycaemic drugs - willing to provide written informed consent

Exclusion criteria

Exclusion criteria: - patients of type 1 diabetes, - patients on insulin treatment - secondary diabetes - complications on or during treatment plan - known or suspected hypersensitivity to study drugs - co-morbid illness like cardiovascular diseases, renal failure or liver diseases

Design outcomes

Primary

Measure	Time frame
change in HbA1c levelTimepoint: day 0 and at end of 3 months	—

Secondary

Measure	Time frame
Cost effectivenessTimepoint: at end of 3 months;fasting plasma glucoseTimepoint: day 0, week 2, 1st month, 2nd month and 3rd month;Postprandial glucoseTimepoint: day 0, week 2, 1st month, 2nd month and 3rd month	—

Countries

India

Contacts

Public ContactDr CD Tripathi

Vardhman Mahavir Medical College and Safdarjung Hospital

drsurajpanchal@gmail.com09718757414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026